ArticleThe Pan African medical journal2025
Mpox in a non-HIV immunosuppressed host: a case report from Nigeria.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a lack of studies describing the impact of mpox in non-HIV immunosuppressed conditions such as severe autoimmune disorders, haematologic malignancies, solid organ transplant recipients, and those on immunosuppressive medications. Here, we report a case of mpox in a 52-year-old female with background diabetes mellitus and rheumatoid arthritis on 18 months of immunosuppressive drugs (prednisolone and methotrexate) who presented to an mpox treatment center at the University of Port Harcourt Teaching Hospital, Rivers State, Nigeria with disseminated febrile rash syndrome and a history of sexual exposure with a heterosexual partner with a febrile rash. Monkeypox virus (MPXV) and varicella-zoster virus (VZV) DNA levels in lesional swabs were quantified by qPCR, which returned positive and negative, respectively. Genomic sequencing was performed, and clade 2b was identified as the infecting clade of the virus. She was seronegative to HIV 1 and 2 (ELISA). Despite having a high burden of skin rash (>500 lesions), confluent skin distribution, and systemic complications, she essentially recovered on supportive treatment, highlighting her reduced net state of immunosuppression. This case report of mpox in a Nigerian lady with background immunosuppression successfully managed by a multidisciplinary team underscores the need for proactive screening and timely management of mpox to prevent unfavorable outcomes. Further studies are needed to understand the burden and outcome of mpox in the non-HIV immunosuppressive population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.